The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
FDA approves axatilimab for the treatment of cGvHD
On August 14, 2024, the U.S. Food and Drug Administration (FDA) granted approval to axatilimab, a colony stimulating factor-1 receptor-blocking antibody, for the treatment of chronic graft-versus-host disease (cGvHD) after ≥2 prior lines of systemic therapy in both adult and pediatric patients who weigh ≥40 kg.1
This approval was based on data from the phase II, randomized, open-label, multicenter AGAVE-201 trial (NCT04710576), which evaluated axatilimab at 3 different dose levels in patients with recurrent or refractory cGvHD.1
Pivotal data from AGAVE-2011
- In total, 79 patients were treated at the final recommended dose of 0.3 mg/kg to a maximum dose of 35 mg, as an infusion every 2 weeks until progression or toxicity deemed unacceptable.
- The overall response rate at the recommended dose was 75%.
- The median time to first response was 1.5 months and the median duration of response was 1.9 months.
- The most common adverse events included increased aspartate aminotransferase, infections, and increased alanine aminotransferase.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content